Macy’s, Inc. Reports Third Quarter 2021 Results

*Comparable sales up 37.2% on an owned basis and up 35.6% on an owned-plus-licensed basis versus 2020; up 8.9% and up 8.7%, respectively, versus 2019
*Diluted EPS of $0.76 and Adjusted diluted EPS of $1.23
*Repurchased $300 million of shares, repaid $1.6 billion in debt ahead of schedule and paid $46 million in dividends
*Added 4.4 million new customers into Macy’s brand, a 28% increase over 2019

“Our company delivered another strong quarter and exceeded our expectations on both top and bottom lines. The results were driven by the effective execution of the Polaris strategy and an improved economic environment. In the quarter, the Macy’s brand added 4.4 million new customers. Consumers continue to spend, and we successfully offered a wide range of expanding merchandise assortment to meet their growing demand,” said Jeff Gennette, chairman and chief executive officer of Macy’s, Inc. “Looking ahead to the fourth quarter, we remain a special place for holiday shopping, and our robust omnichannel ecosystem is showing resilience in the face of labor and supply chain challenges and enables us to meet customer shopping needs with speed and convenience.”

“We are encouraged by the momentum of our business and its strong financial health and continue to invest in positioning our company for long-term sustainable and profitable growth,” Gennette continued. “Today, we are announcing plans to launch a curated digital marketplace platform that will further fuel customer acquisition and sales growth across all of our channels.”
details at: https://www.macysinc.com/investors/news-events/press-releases/detail/1722/macys-inc-reports-third-quarter-2021-results-narrows

Related Posts

News Corp Reports First Quarter Results for Fiscal 2023

Fiscal 2023 First Quarter Key Financial Highlights *Revenues in the quarter were $2.48 billion, a 1% decrease compared to $2.50 billion in the prior year, driven by a $153 million, or 6%, negative impact from foreign currency fluctuations and lower Book Publishing segment revenues. Adjusted Revenues increased 3% *Net income in the quarter was $66 million compared to $267 million in the prior year *Total Segment EBITDA in the quarter was $350 million compared to $410 million in the prior year

The New York Times Company Reports Fourth-Quarter 2022 Results

The New York Times Company announced fourth quarter 2022 diluted earnings per share from continuing operations of $.43 compared with $.41 in the same period of 2021. Adjusted diluted earnings per share from continuing operations (defined below) was $.59 in the fourth quarter of 2022 compared with $.43 in the fourth quarter of 2021. Operating profit decreased to $93.0 million in the fourth quarter of 2022 from $94.1 million in the same period of 2021 as higher digital subscription revenues at The New York Times Group segment (“NYTG”) and the impact from six additional days in the quarter were more than offset by a one-time charge related to the Company’s withdrawal from a multiemployer pension plan and operating losses at The Athletic segment (“The Athletic”). Adjusted operating profit (defined below) increased to $141.8 million from $109.3 million in the prior year, as higher digital subscription revenues at NYTG and the impact from the additional six days more than offset operating losses at The Athletic. Adjusted operating profit at NYTG increased to $148.7 million from $109.3 million as higher digital subscription and other revenues more than offset lower digital advertising revenues.

European Academy of Allergy and Clinical Immunology Extends Publishing Partnership with Wiley

The European Academy of Allergy and Clinical Immunology (EAACI) and John Wiley & Sons Inc., a global leader in research and education, have expanded their publishing partnership to include EAACI’s official open access journal Clinical and Translational Allergy (CTA) alongside their other publications, Allergy and Pediatric Allergy and Clinical Immunology, as of January 2021. CTA is a fully open access journal, edited by Prof. Jean Bousquet and Dr. Clive Grattan, and provides a dissemination of allergy research and reviews, as well as EAACI position papers, task force reports, and guidelines for an international scientific audience. “We are delighted to extend our collaboration with Wiley to include CTA in 2021. Having all three journals under the same publishing umbrella will allow them to benefit from Wiley's extensive expertise in the publishing process, while at the same time keeping up the high quality of EAACI's scientific content, including the most relevant progress and updates in the field." Tomàs Chivato, EAACI VP Science; Jean Bousquet, CTA Editor-in-Chief; Clive Grattan, CTA Editor-in-Chief.
Back To Top
×Close search
Search